Lutetium-177 labelled edotreotide

Drug Profile

Lutetium-177 labelled edotreotide

Alternative Names: 177Lu-DOTATOC; 177Lu-edotreotide; 177Lu-edotreotide PRRT; Peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide; Solucin

Latest Information Update: 02 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ITM Solucin
  • Class Antineoplastics; Radiopharmaceuticals
  • Mechanism of Action Positron-emission tomography enhancers; Somatostatin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroendocrine tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Neuroendocrine tumours

Most Recent Events

  • 02 Feb 2017 Phase-III clinical trials in Neuroendocrine tumours in Australia (IV) (NCT03049189)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top